From Level 3 to Level 4: A Complete Dermatology E/M Documentation Guide

Two dermatologists can see the same psoriasis patient on the same day, deliver the same care, and bill different levels based entirely on what the note says. Payer algorithms score note language, not the clinical event.

Cigna, Aetna, and Anthem now score note language against their own rubrics and shift Level 4 claims to Level 3 before a human opens the chart. The 2021/2023 E/M revisions, still in force for 2026, stripped history and exam as scoring elements and left dermatologists two paths to Level 4. Most derm charts are still written for the old rules.

Under the AMA's 2023 E/M guidelines, a level is set by medical decision-making (MDM) or by total time on the date of encounter. Not both. Pick the path that reflects the visit and commit to it.

Time thresholds for established patients: 99213 is 20–29 minutes, 99214 is 30–39 minutes, 99215 is 40–54 minutes. For new patients: 99203 is 30–44, 99204 is 45–59, 99205 is 60–74. AAFP is explicit that choosing both paths in the same note "could confuse auditors."

MDM needs two of three elements at the target level. Problems Addressed, Data Reviewed, and Risk. Level 4 is moderate complexity: a chronic illness with exacerbation or treatment side effects, or an undiagnosed problem with uncertain prognosis. Moderate Data means ordering and reviewing external records, independently interpreting a test, or discussing management with another physician. Moderate Risk, for dermatology, is almost always prescription drug management.

Prescription drug management is the most common Moderate Risk lever in dermatology and also the most commonly mis-documented. AAFP is specific: refilling or continuing a prescription counts only if the note captures what the medication is for, any dose adjustments, and how it ties to the problem addressed. "Continue clobetasol" does not clear that bar. "Continuing clobetasol 0.05% BID for plaque psoriasis of elbows; patient progressing but not at treatment goal after 6 weeks; monitoring for skin atrophy" does.

Dose also determines risk tier. Prescription-strength topicals tied to a documented clinical rationale support Moderate Risk. OTC-strength recommendations do not. "Use hydrocortisone 1% OTC" on a new eczema patient reads to an auditor as Low Risk regardless of how complex the differential was.

Clarity's coding team calls the fix "Think in Ink." Replace "stable" with language that describes the actual clinical picture: exacerbated, progressing, not at treatment goal, side effects of treatment. Every one of those phrases maps directly to the AMA's moderate-complexity definitions. "Stable" does not, which is how Level 4 visits get downcoded to Level 3 without the payer ever looking at the chart.

The prescription note itself needs four elements to survive audit: the clinical rationale, associated risks or monitoring, whether the patient has failed other medications, and whether they're a candidate for alternatives. That's what moves a visit from Low Risk to Moderate Risk and holds up when a reviewer works the chart.

The OIG's November 2025 dermatology audit found 61.5% of E/M claims include a same-day procedure, and payers know it. The CMS MLN006764 booklet defines modifier 25 as "significant and separately identifiable," and the operational interpretation is the cross-out test: strip every line related to the procedure from the note, and the remaining documentation must independently support the E/M level billed.

A note that reads "skin check, biopsied cheek lesion, continue eczema meds" fails immediately. Remove the biopsy line and what's left is "continue eczema meds," which supports nothing. Prior TPL coverage of the OIG findings and BCBSM's May 1 modifier 25 cut details how payers are tightening.

Chronic plaque psoriasis, established. Before: "Psoriasis stable. Continue clobetasol. RTC 3 months." After: "Moderate plaque psoriasis of elbows and scalp, progressing despite clobetasol 0.05% BID for 6 weeks. Not at treatment goal (BSA 4% to ~7%). Failed topical calcipotriene 2024. Candidate for step-up to oral methotrexate vs biologic; discussed risk/benefit including LFT monitoring. Prescribed methotrexate 15 mg weekly with folic acid. Baseline CBC/CMP ordered. Level set by MDM: 1 chronic illness with exacerbation + prescription drug management."

New patient, suspicious pigmented lesion. Before: "Changing mole on back. Will biopsy. Rx triamcinolone for eczema on arms." After: "55yo male, 8mm pigmented lesion L upper back, irregular borders, color variegation, changed over ~3 months. Father with melanoma. Differential: atypical nevus vs early melanoma. Shave biopsy performed. Separately evaluated nummular eczema B arms, failed OTC hydrocortisone, started triamcinolone 0.1% BID. Level set by MDM: undiagnosed new problem with uncertain prognosis + prescription drug management. Modifier 25 supported."

Isotretinoin management. Before: "Acne improved. Continue Accutane. Labs ordered." After: "Moderate-severe nodulocystic acne, month 3 of isotretinoin 40 mg daily, cumulative 72 mg/kg of planned 120–150. ~50% improvement with new cheilitis and xerosis, side effects managed. iPLEDGE confirmed, pregnancy test negative, LFTs/lipids reviewed. Level set by MDM: chronic illness with side effects + prescription drug management with lab monitoring."

Same-day skin check plus biopsy. After: "Annual full-body skin exam. 5mm pearly papule R nasolabial fold, clinically concerning for BCC. Shave biopsy (11102). Separately, eczema flare on hands over 2 weeks not responsive to OTC, failed prior tacrolimus 2023. Started triamcinolone 0.1% ointment. E/M work separate and significant from biopsy decision; cross-out test applied. Level set by MDM: chronic illness with exacerbation + prescription drug management."

Rosacea with doxycycline initiation. After: "Moderate papulopustular rosacea, progressing despite metronidazole 0.75% gel BID x 3 months. Not at treatment goal. Failed ivermectin 1% cream 2024. Prescribed doxycycline 40 mg modified-release daily, counseled on photosensitivity, GI upset, OCP interaction. Ocular involvement, referral placed. Level set by MDM: chronic illness with exacerbation + prescription drug management."

Clarity RCM manages revenue cycle for 200+ dermatology practices across 42 states. It's all we do. See how we work.